ZAPI GROUP Expands Electric Drive Charging Solutions with the Strategic Acquisition of Stercom Power Solutions
Article content
Article content
Stercom Power Solutions contributes pioneering technologies in energy storage and charging systems for e-mobility and industrial energy systems. This expansion in capabilities reinforces ZAPI GROUP's position as an industry leader in electric drive and industrial automation solutions that will accelerate innovation and deliver more comprehensive solutions to the market.
Article content
Article content
'The acquisition of Stercom Power Solutions represents an important milestone in our growth strategy and demonstrates our ongoing commitment to expanding our capabilities to better serve our customers,' said Mr. Giannino Zanichelli, founder and owner of ZAPI GROUP. 'This acquisition strengthens ZAPI GROUP's ability to deliver next-generation charging solutions as demand accelerates for advanced technologies in electric drive applications. The addition of this company's innovative product portfolio and talented team will help drive continued growth and market leadership.'
Article content
ZAPI GROUP is committed to a seamless integration for Stercom Power Solutions, ensuring continuity for their customers. As part of this process, Stercom Power Solutions will continue to operate as an independent entity in Bavaria, Germany, closely aligned with the rest of the ZAPI GROUP companies.
Article content
About ZAPI GROUP
Article content
ZAPI GROUP is engineering the transition to an all-electric future with a highly integrated product portfolio, including motion controllers, electric motors, and high-frequency battery chargers for application in full-electric and hybrid vehicles. We provide turnkey system integration, autonomous navigation software, and safety and asset tracking for fleet management. As a global electrification leader with deep systems experience, leading innovations, and an obsession with driving customers' success, ZAPI GROUP now counts more than 1700 employees worldwide with a total annual revenue of more than 700 million US dollars. For more information, visit www.zapigroup.com.
Article content
Article content
Article content
Article content
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Globe and Mail
an hour ago
- Globe and Mail
BD Stock Gains in Pre-Market Following Q3 Earnings Beat, Margins Up
Becton, Dickinson and Company BDX, popularly known as BD, delivered adjusted earnings per share (EPS) of $3.68 in the third quarter of fiscal 2025, up 5.1% year over year. The figure topped the Zacks Consensus Estimate by 7.6%. The adjustments include expenses related to purchase accounting adjustments and restructuring costs, among others. GAAP EPS for the quarter was $2.00, reflecting an uptick of 19% from the year-ago figure. BDX's Revenues in Detail BD registered revenues of $5.51 billion in the fiscal third quarter, up 10.4% year over year on a reported basis. The figure surpassed the Zacks Consensus Estimate by 0.5%. At constant exchange rate (CER), revenues climbed 9.9% year over year. Adjusted revenues (which excludes the recognition of accruals relating to the Italian government medical device payback legislation, as well as another legal matter) in the fiscal third quarter was $5.51 billion, up 8.9% year over year on a reported basis, 8.5% at CER and 3% on an organic basis. Robust performance by the BD Medical and BD Interventional segments drove the top-line improvement. Shares of this company gained nearly 9.8% in today's pre-market trading. BD's Segment Details BD's operations consist of three worldwide business segments — BD Medical, BD Life Sciences and BD Interventional. In the quarter under review, BD Medical reported worldwide revenues of $2.93 billion, up 14.4% from the year-ago quarter on a reported basis, 14% at CER and 3.2% on an organic basis. Per management, the segment's organic revenue growth reflected mid-single digit growth in Medication Management Solutions and Pharmaceutical Systems (PS) and low single-digit growth in Medication Delivery Solutions (MDS) business units. This figure compares to our fiscal third-quarter revenue projection of $3.01 billion. Worldwide revenues in the BD Life Sciences segment totaled $1.25 billion, down 0.5% year over year on a reported basis and 1.1% both at CER and on an organic basis. The segment's performance reflected declines in Diagnostic Solutions (DS) and Biosciences (BDB) business units. This was partially offset by low single-digit growth in the Specimen Management business unit. This figure compares to our fiscal third-quarter revenue projection of $1.21 billion. BD Interventional segment generated worldwide revenues of $1.33 billion, up 7.2% from the year-ago quarter on a reported basis and 6.8% both at CER and on an organic basis. The segment's performance reflected double-digit growth in Urology & Critical Care and mid-single-digit growth in Surgery and Peripheral Intervention. This figure compares to our fiscal third-quarter revenue projection of $1.28 billion. BDX's Geographic Results In the third quarter of fiscal 2025, revenues in the United States improved 10% year over year to $3.18 billion. This figure compares to our fiscal third-quarter revenue projection of $3.21 billion. Adjusted revenues in the United States in the fiscal third quarter were $3.18 billion, up 9.8% year over year on a reported basis. International revenues grossed $2.33 billion, up 10.9% from the year-ago quarter on a reported basis and up 9.8% at CER. This figure compares to our fiscal third-quarter revenue projection of $2.28 billion. Adjusted International revenues in the fiscal third quarter were $2.33 billion, up 7.8% year over year on a reported basis and up 6.7% at CER. BD's Margin Analysis In the quarter under review, BD's gross profit increased 14.2% year over year to $2.63 billion. The gross margin expanded 158 basis points (bps) to 47.8%. We had projected a gross margin of 44.9% in the third quarter of fiscal 2025. Selling and administrative expenses increased 10.4% year over year to $1.32 billion. Research and development expenses decreased 0.7% year over year to $297 million. Adjusted operating expenses of $1.62 billion rose 8.2% year over year. Adjusted operating profit totaled $1.02 billion, reflecting a 25.2% increase from the year-ago quarter. The adjusted operating margin in the fiscal third quarter expanded 219 bps to 18.5%. BDX's Financial Position BD exited third-quarter fiscal 2025 with cash and cash equivalents and short-term investments of $757 million compared with $683 million at the fiscal second-quarter end. Total debt (including current debt obligations) at the end of the fiscal third quarter was $19.34 billion compared with $19.27 billion at the fiscal second-quarter end. Cumulative net cash provided by continuing operating activities at the end of third-quarter fiscal 2025 was $2.08 billion compared with $ 2,67 billion a year ago. Meanwhile, BD has a consistent dividend-paying history, with its five-year annualized dividend growth being 5.39%. BD's Fiscal 2025 Guidance BD has revised its financial outlook for fiscal. BD continues to project its full fiscal year revenues between $21.8 billion and $21.9 billion. The Zacks Consensus Estimate is pegged at $21.83 billion. However, the rate of revenue growth is now projected to be 8.2-8.7% from the comparable fiscal 2024 period, up from the prior outlook of 8-8.5% on a reported basis from the comparable fiscal 2024 period. For fiscal 2025, adjusted revenues at CER are expected to continue to reflect growth in the range of 7.8-8.3% from the comparable fiscal 2024 period. Organic revenue growth is continued to be expected between 3% and 3.5% from the comparable fiscal 2024 period. For the full fiscal year, adjusted EPS is now anticipated to be in the range of $14.30-$14.45 (representing growth of 8.8-10% from the comparable fiscal 2024 period), up from the previous outlook of $14.06-$14.34 (representing growth of 7-9.1% from the comparable fiscal 2024 period). The Zacks Consensus Estimate is pegged at $14.17. Our Take on BDX BD exited the third quarter of fiscal 2025 with better-than-expected results and solid top and bottom-line results. Robust performances by its Medical and Interventional segments and both geographic regions were encouraging. Strength in BD's segments' business units during the reported quarter was also promising. The expansion of both margins bodes well. Per management, BD Excellence operating system is driving continued margin expansion. This looks promising for the stock. Apart from these, there were a few other developments during the recent period, like its definitive agreement to combine BD's BDB and DS business units with Waters Corporation. The transaction is expected to create an innovative life science and diagnostics leader with an industry-leading financial outlook focused on regulated, high-volume testing. BD Medical segment's MDS business unit announced its plans to invest $35 million in Nebraska facility to support new BD PosiFlush Prefilled Flush Syringe production lines, product innovation and operational efficiencies, while the PS business unit announced the first pharma-sponsored combination product clinical trial using the BD Libertas Wearable Injector for subcutaneous delivery of complex biologics. However, BD's lower revenues from its Life Sciences segment were disappointing. BD's Zacks Rank and Stocks to Consider BDX currently carries a Zacks Rank #4 (Sell). Some better-ranked stocks in the broader medical space that have announced quarterly results are GE HealthCare Technologies Inc. GEHC, West Pharmaceutical Services, Inc. WST and Boston Scientific Corporation BSX. GE HealthCare, sporting a Zacks Rank #1 (Strong Buy), reported second-quarter 2025 adjusted EPS of $1.06, beating the Zacks Consensus Estimate by 16.5%. Revenues of $5.01 billion outpaced the consensus mark by 0.7%. You can see the complete list of today's Zacks #1 Rank stocks here. GE HealthCare has a long-term estimated growth rate of 5.8%. GEHC's earnings surpassed estimates in each of the trailing four quarters, the average surprise being 12.5%. West Pharmaceutical reported second-quarter 2025 adjusted EPS of $1.84, beating the Zacks Consensus Estimate by 21.9%. Revenues of $766.5 million surpassed the Zacks Consensus Estimate by 5.4%. It currently flaunts a Zacks Rank #1. West Pharmaceutical has a long-term estimated growth rate of 8.4%. WST's earnings surpassed estimates in each of the trailing four quarters, the average surprise being 16.8%. Boston Scientific reported second-quarter 2025 adjusted EPS of 75 cents, beating the Zacks Consensus Estimate by 4.2%. Revenues of $5.06 billion surpassed the Zacks Consensus Estimate by 3.5%. It currently carries a Zacks Rank #2 (Buy). Boston Scientific has a long-term estimated growth rate of 14%. BSX's earnings surpassed estimates in each of the trailing four quarters, the average surprise being 8.1%. Beyond Nvidia: AI's Second Wave Is Here The AI revolution has already minted millionaires. But the stocks everyone knows about aren't likely to keep delivering the biggest profits. Little-known AI firms tackling the world's biggest problems may be more lucrative in the coming months and years. See "2nd Wave" AI stocks now >> Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Boston Scientific Corporation (BSX): Free Stock Analysis Report Becton, Dickinson and Company (BDX): Free Stock Analysis Report West Pharmaceutical Services, Inc. (WST): Free Stock Analysis Report GE HealthCare Technologies Inc. (GEHC): Free Stock Analysis Report
CTV News
4 hours ago
- CTV News
Canadian Natural Resources says Q2 profit, production increased
Canadian Natural Resources Ltd., at the company's annual meeting in Calgary on May 3, 2012. THE CANADIAN PRESS/Jeff McIntosh
Globe and Mail
4 hours ago
- Globe and Mail
STE Beats on Q1 Earnings and Revenues, Raises '26 Sales View
STERIS plc STE reported first-quarter fiscal 2026 adjusted earnings per share (EPS) of $2.34, up 15.3% from the year-ago quarter's figure. The figure surpassed the Zacks Consensus Estimate by 0.9%. The adjustment excludes the impacts of certain non-recurring charges, such as the amortization of acquired intangible assets and acquisition and integration-related charges. The company's GAAP EPS was $1.79, up 27% from the year-ago level of $1.41. Following the earnings announcement, STE stock remained unchanged in after-market trading yesterday. STE's Q1 Revenues in Detail Revenues of $1.39 billion from continuing operations increased 8.6% year over year. The figure missed the Zacks Consensus Estimate by 2.4%. Organic revenues at constant exchange rate or CER rose 8% year over year. STE's Quarterly Performance in Detail The company operates under three segments — Healthcare, Applied Sterilization Technologies ('AST') and Life Sciences. Revenues at Healthcare rose 8% year over year to $974.7 million (up 8% on a CER organic basis). This reflected 5% growth in consumable revenues, a 13% rise in service revenues and a 6% improvement in capital equipment revenues. Our model expected Healthcare segment revenues to improve 5.2% in the fiscal first quarter. Revenues from AST improved 13% to $281.2 million (up 10% on a CER organic basis). This performance reflected 12% growth in service revenues and a 46% increase in capital equipment revenues. Our model anticipated a 6.3% improvement in the segment's quarterly revenues. Revenues from the Life Sciences segment increased 5% to $135.2 million (up 4% year over year on a CER organic basis). This performance reflected 8% growth in consumable revenues, a 3% rise in service revenues and a 1% improvement in capital equipment revenues. Our model projected a year-over-year increase of 6% for the segment's revenues. Margins The gross profit in the reported quarter was $628 million, up 9.7% from the prior-year level. The gross margin expanded 41 basis points (bps) year over year to 45.1% despite a 7.9% increase in the cost of revenues. STERIS witnessed a 5.4% year-over-year rise in selling, general and administrative expenses. The figure amounted to $353.8 million. Research and development expenses rose 3.1% to $26.4 million. Adjusted operating expenses totaled $380.2 million, up 5.3% year over year. The adjusted operating margin expanded 131 bps to 17.8%. Financial Details STERIS exited the first quarter of fiscal 2026 with cash and cash equivalents of $279.7 million compared with $171.7 million at the end of fiscal 2025. STERIS plc Price, Consensus and EPS Surprise Net cash flow from operating activities at the end of the fiscal first quarter was $420 million compared with $303.7 million in the year-ago period. Further, the company has a five-year annualized dividend growth rate of 9.03%. Guidance STERIS raised its fiscal 2026 revenue projection. It now expects revenues from continuing operations to increase approximately 8-9%, up from the previous projection of 6-7%. The Zacks Consensus Estimate is pegged at $5.83 billion, implying 6.8% growth from fiscal 2025. Constant currency organic revenues are expected to improve approximately 6-7%. Adjusted EPS is expected to be in the range of $9.90-$10.15. The Zacks Consensus Estimate for the metric is pegged at $10.12. Our Take STERIS ended first-quarter fiscal 2026 on a solid note, wherein both earnings and revenues beat estimates. All business segments experienced growth during the quarter. The year-over-year top-line growth can be attributed to favorable foreign currency. Meanwhile, expansion of both margins, despite tariff headwinds, bodes well for the stock. Furthermore, the raised sales guidance for fiscal 2026 looks encouraging. STE's Zacks Rank & Key Picks STE currently carries a Zacks Rank #3 (Buy). Some better-ranked stocks from the broader medical space are Boston Scientific BSX, Cardinal Health CAH and Cencora COR. Boston Scientific, carrying a Zacks Rank #2 (Buy) at present, reported a second-quarter 2025 adjusted EPS of 75 cents, which beat the Zacks Consensus Estimate by 4.2%. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. Revenues of $5.06 billion topped the Zacks Consensus Estimate by 2.3%. BSX has a long-term earnings growth rate of 14% compared with the industry's 14.2%. Cardinal Health, carrying a Zacks Rank #2 at present, posted third-quarter fiscal 2025 adjusted EPS of $2.35, which exceeded the Zacks Consensus Estimate by 9.3%. Revenues of $54.88 billion missed the Zacks Consensus Estimate by 0.3%. CAH has an estimated long-term earnings growth rate of 10.9% compared with the industry's 9.9%. Cencora currently carries a Zacks Rank #2. The Zacks Consensus Estimate for third-quarter fiscal 2025 adjusted EPS is currently pegged at $3.78 and the same for revenues is pinned at $80.33 billion. Cencora has an estimated long-term growth rate of 12.8%. COR's earnings yield of 5.4% compares favorably with the industry's 4.1%. Beyond Nvidia: AI's Second Wave Is Here The AI revolution has already minted millionaires. But the stocks everyone knows about aren't likely to keep delivering the biggest profits. Little-known AI firms tackling the world's biggest problems may be more lucrative in the coming months and years. See "2nd Wave" AI stocks now >> Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Boston Scientific Corporation (BSX): Free Stock Analysis Report Cardinal Health, Inc. (CAH): Free Stock Analysis Report Cencora, Inc. (COR): Free Stock Analysis Report STERIS plc (STE): Free Stock Analysis Report
